Urogen Pharma Ltd
(URGN)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 03-2023 | 12-2022 | 09-2022 | 06-2022 | 03-2022 | |
| Sales | 17,192 | 18,092 | 16,097 | 16,604 | 13,564 |
| Cost of Goods | 2,265 | 2,263 | 2,020 | 1,846 | 1,525 |
| Gross Profit | 14,927 | 15,829 | 14,077 | 14,758 | 12,039 |
| Operating Expenses | 37,237 | 36,374 | 32,184 | 34,319 | 34,521 |
| Operating Income | -22,045 | -20,282 | -18,087 | -18,715 | -21,957 |
| Interest Expense | 3,553 | 3,223 | 2,694 | 2,239 | 282 |
| Other Income | -4,594 | -4,675 | -4,341 | -5,705 | -5,828 |
| Pre-tax Income | -30,192 | -28,180 | -25,122 | -26,659 | -28,067 |
| Income Tax | 21 | 689 | 709 | 32 | 325 |
| Net Income Continuous | -30,213 | -28,869 | -25,831 | -26,691 | -28,392 |
| Net Income | $-30,213 | $-28,869 | $-25,831 | $-26,691 | $-28,392 |
| EPS Basic Total Ops | -1.30 | -1.25 | -1.13 | -1.18 | -1.25 |
| EPS Basic Continuous Ops | -1.30 | -1.25 | -1.13 | -1.18 | -1.25 |
| EPS Diluted Total Ops | -1.30 | -1.25 | -1.13 | -1.18 | -1.25 |
| EPS Diluted Continuous Ops | -1.30 | -1.25 | -1.13 | -1.18 | -1.25 |
| EBITDA(a) | $-22,182 | $-20,451 | $-18,110 | $-18,362 | $-21,692 |